STOCK TITAN

SION insider files Form 144 to sell 10,250 shares valued $251.6K

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sionna Therapeutics, Inc. (SION) filing a Form 144 notifies a proposed sale of 10,250 common shares via Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $251,637.50. The shares were acquired and paid for on 09/04/2025 through exercise of stock options from the issuer. The filing lists 44,139,823 shares outstanding and reports no other sales by the seller in the past three months. The filer certifies no undisclosed material adverse information.

Positive

  • Timely disclosure of proposed sale via Form 144 meets regulatory notice requirements
  • Transaction sourced from option exercise and fully paid on the acquisition date (09/04/2025)
  • No other sales in past three months reported for the seller

Negative

  • Insider sale of shares could be perceived negatively by some investors despite being small
  • Limited contextual information about the identity of the selling person and motive is not provided in the filing

Insights

TL;DR Insider exercised options and plans a small public sale representing a negligible fraction of outstanding shares.

The filing documents a routine Form 144 sale following an option exercise and immediate payment on 09/04/2025. At 10,250 shares valued at $251,637.50 against 44,139,823 shares outstanding, the position is immaterial to capitalization and unlikely to move the market. Timely disclosure via Form 144 satisfies Rule 144 notice requirements and shows compliance with resale regulations.

TL;DR The notice reflects standard insider liquidity post-exercise with required certifications about material information.

The filer affirms no nonpublic material adverse information and indicates no prior sales in the past three months. This aligns with disclosure expectations for insiders selling securities obtained from option exercises. The broker identified and the exchange specified (NASDAQ) provide clear execution pathways. The disclosure does not raise governance or compliance concerns based on the provided facts.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What is being reported in the SION Form 144?

The filing reports a proposed sale of 10,250 common shares valued at $251,637.50, to be sold on NASDAQ through Morgan Stanley Smith Barney.

When were the shares acquired and how were they paid for?

The shares were acquired and paid for on 09/04/2025 via exercise of stock options with payment in cash.

How large is the sale relative to Sionna's outstanding shares?

The proposed sale is 10,250 shares versus 44,139,823 shares outstanding, representing an immaterial percentage of total shares.

Did the filer report any other sales in the past three months?

The Form 144 indicates Nothing to Report for securities sold during the past three months by the seller.

Which broker and exchange are named for the sale?

The broker is Morgan Stanley Smith Barney LLC and the exchange is specified as NASDAQ.
Sionna Therapeutics

NASDAQ:SION

SION Rankings

SION Latest News

SION Latest SEC Filings

SION Stock Data

1.84B
29.91M
7.01%
97.98%
7.87%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM